News | August 20, 2014

New Dementia Research Reveals Overwhelming Demand for ‘Value of Knowing’

August 20, 2014 — Three out of four people would want to know what kind of neurological disorder they had, even if there was no cure, according to new global research from GE Healthcare. An even higher percentage of respondents, 81 percent, would want to identify an incurable neurological disorder if it affected somebody close to them, with more women (84 percent) wanting to know than men (76 percent). The “Value of Knowing” global survey of 10,000 adults across 10 countries explored perspectives on incurable neurological disorders including Alzheimer’s (AD) and Parkinson’s (PD) disease.

Prepared to Pay for Diagnosis

While the overwhelming consensus (94 percent) is that government or health insurance providers should cover diagnosis, approximately half (51 percent) of respondents indicated they would even be prepared to pay for a diagnosis themselves. This sentiment was particularly prevalent in India and China, where 71 percent and 83 percent respectively, said they would be prepared to pay. This was echoed by almost one half of those questioned in Russia and around one-third of respondents in the United Kingdom, United States and Japan.

“What these statistics tell us is just how strongly people feel about tackling neurological disorders like dementia,” said Marc Wortmann, executive director of Alzheimer’s Disease International. “Worldwide, nearly 44 million people have dementia, and this number is expected to nearly double in 20 years as the world’s population ages. Although there is no cure yet, a timely diagnosis is useful for people with dementia to get access to current treatment, services and support, both medical and non-medical.”

When people surveyed were asked why they would want to know, the most common answer (71 percent) was to start treatment that could help manage the symptoms of the disease. Other reasons included the opportunity to change their lifestyle to potentially slow the impact of the illness (66 percent), and the ability to make informed decisions (62 percent). Those who would not want to know cited undue worry and the futility of knowing about their disorder without being able to control it.

Ben Newton, director of PET (positron emission tomography) neurology for GE Healthcare, said, “It’s understandable that dementia is a frightening topic for people. That said, although there are currently no cures for many neurological disorders, there are symptom-modifying therapies and approaches available if detected early enough. It’s interesting to note that the majority of respondents with more experience of a neurological disorder via a loved one for example, said that they would want to know, in spite of there being no cure.”

Recognizing the Symptoms

The research also probed respondents’ recognition of the possible signs and symptoms of dementia. While a majority recognized memory loss (70 percent) and disorientation (61 percent) as signs of dementia, less than half of those surveyed were able to identify other very common symptoms, including language problems, personality, mood and behavior changes, and loss of initiative.

Newton added, “Understanding and knowing all the symptoms of a neurological disorder are critical to helping loved ones who may be showing early signs. Acting early on any concerns may mean patients have access to earlier diagnosis and intervention, which could help to manage and delay the impact of a disorder.”

US Specific Country Findings

The U.S. recorded 80 percent willingness to know. In addition, U.S. women wanted to know their own diagnosis more than men (81 percent vs. 79 percent). Eighty-five percent of U.S. respondents said they would want access to early diagnosis, and 96 percent feel early diagnosis should be covered by health insurance.

The research was conducted by Millward Brown during June 2014 across 10 countries — Australia, Brazil, China, India, Indonesia, Japan, Russia, South Korea, U.K. and U.S. — with 1,000 nationally representative adult respondents in each market.

For more information: www.gehealthcare.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init